Quintiles to deliver AstraZeneca’s clinical pharmacology studies

Quintiles today announced that it has entered into in an industry-leading clinical pharmacology alliance with AstraZeneca to deliver AstraZeneca’s clinical pharmacology studies across multiple therapy areas and around the globe.

As a result of the alliance, Quintiles will assume the operational responsibilities for the majority of AstraZeneca’s clinical pharmacology delivery. AstraZeneca and Quintiles will work together, focusing their efforts on leveraging leading-edge science and establishing operational efficiency and consistency to support AstraZeneca’s goal to shorten delivery timelines and bring innovative medicines more quickly to patients.

The alliance is extensive and involves the engagement of a sole provider for clinical pharmacology delivery, and a simple, standardized pricing model. Also, as well as clinical conduct and medical oversight of studies, the agreement covers a range of activities across the end-to-end study process.

Ron Wooten, Executive Vice President, Quintiles Corporate Development, said, “We are delighted to be AstraZeneca’s dedicated clinical pharmacology alliance strategic partner. This is an industry-leading alliance and demonstrates how, at Quintiles, we’re helping the industry seize opportunities as the industry transforms in response to the changing environment. As with any true alliance, success depends not only on scientific, medical and operational excellence, but also on creating a climate of trust, transparency, teamwork and joint accountability. Our experience in managing such partnerships will be key as we work together on this important project.”

Commenting on the alliance, Anders Ekblom, Executive Vice President for Global Drug Development, AstraZeneca, said, “This model gives us access to the right scientific and medical expertise plus the quality, flexibility and capacity we need to work efficiently and cost-effectively to deliver these studies. Finding more efficient ways to do our work, whilst maintaining the highest quality, is one of AstraZeneca’s key priorities. Our alliance with Quintiles will contribute to AstraZeneca’s continued endeavors to develop better and better medicines faster.”

Quintiles has an industry leading, network of clinical pharmacology facilities across Europe and the United States, and plans to open a unit in Asia in 2010. These facilities are connected via integrated data platforms using advanced electronic data capture and reporting to facilitate early go-no go decisions.




Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Quintiles. (2020, April 03). Quintiles to deliver AstraZeneca’s clinical pharmacology studies. News-Medical. Retrieved on December 07, 2022 from https://www.news-medical.net/news/20091103/Quintiles-to-deliver-AstraZenecas-clinical-pharmacology-studies.aspx.

  • MLA

    Quintiles. "Quintiles to deliver AstraZeneca’s clinical pharmacology studies". News-Medical. 07 December 2022. <https://www.news-medical.net/news/20091103/Quintiles-to-deliver-AstraZenecas-clinical-pharmacology-studies.aspx>.

  • Chicago

    Quintiles. "Quintiles to deliver AstraZeneca’s clinical pharmacology studies". News-Medical. https://www.news-medical.net/news/20091103/Quintiles-to-deliver-AstraZenecas-clinical-pharmacology-studies.aspx. (accessed December 07, 2022).

  • Harvard

    Quintiles. 2020. Quintiles to deliver AstraZeneca’s clinical pharmacology studies. News-Medical, viewed 07 December 2022, https://www.news-medical.net/news/20091103/Quintiles-to-deliver-AstraZenecas-clinical-pharmacology-studies.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Quintiles acquires premier provider of genomics testing and analysis